Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).

Cortes, J., Kim, D., Pinilla Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., et al. (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. THE NEW ENGLAND JOURNAL OF MEDICINE, 369(19), 1783-1796 [10.1056/NEJMoa1306494].

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

GAMBACORTI PASSERINI, CARLO;
2013

Abstract

Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).
Articolo in rivista - Articolo scientifico
Young Adult; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Humans; Aged; Protein Kinase Inhibitors; Thrombosis; Imidazoles; Thrombocytopenia; Pyridazines; Aged, 80 and over; Adult; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Adolescent; Female; Male
English
7-nov-2013
369
19
1783
1796
none
Cortes, J., Kim, D., Pinilla Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., et al. (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. THE NEW ENGLAND JOURNAL OF MEDICINE, 369(19), 1783-1796 [10.1056/NEJMoa1306494].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/52070
Citazioni
  • Scopus 853
  • ???jsp.display-item.citation.isi??? 749
Social impact